| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972586 | The Journal of Heart and Lung Transplantation | 2007 | 7 Pages |
Abstract
LVT progression is a powerful risk predictor in light-chain CA, superior to parameters such as LVEF, LVT or a low-voltage pattern. Improved survival by high-dose chemotherapy and stem-cell transplantation is paralleled by a reduction in LVT progression. Repetitive echocardiographic assessment appears indicated in CA patients to identify candidates for heart transplantation in amyloidosis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Arnt V. MD, Jolanta B. MD, Stefan O. MD, Alexander MD, Ute MD, Falk-Udo MD, Hartmut MD, Hugo A. MD, Thomas J. MD,